AIDS drug company Trimeris (NASDAQ:TRMS) this year vetted an initial list of more than 140 companies in all therapeutic areas and narrowed its business combination prospects to 14, then paired that list even further to five. That list included Synageva BioPharma, the company that in June announced it would acquire Trimeris in a reverse merger. […]
AIDS drug company Trimeris‘s (NASDAQ:TRMS) plan to merge with drug development company Synageva BioPharma would give Durham, North Carolina-based Trimeris the buyer it has been seeking and it would provide privately held Synageva a public listing and a U.S. Food and Drug Administration-approved drug. Under terms of the all-stock deal, Synageva will own 75 percent […]
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
AIDS drug company Trimeris (NASDAQ:TRMS) is getting $4.9 million from partner Roche (OTC:RHBBY) to settle a royalties dispute regarding the AIDS drug Fuzeon. Durham, North Carolina-based Trimeris and Swiss pharmaceutical giant Roche have clashed over Fuzeon royalty payments since 2009. Under a development and license agreement between the companies, Fuzeon is manufactured by Roche and […]